Verified Nov 2026
Electronics & Software
·

Berlin, Berlin
·
Since 2015
Medios is a Berlin-based specialty pharmaceutical provider established in 2015, operating across Germany, the Netherlands, Belgium, and Spain with 500-1,000 employees and estimated revenue of €1.8 billion as of 2023. The company composes patient-specific medications, manufactures cytostatic drugs, and distributes high-priced specialty pharmaceuticals for oncology and neurology therapies. Medios acquired a 74% stake in Caelo in 2026 to strengthen its position in active pharmaceutical ingredients and excipients across Europe.
Medios at a glance
Revenue
$1-5B
Est. band
Employees
500-1,000
Founded
2015
Headquarters
Berlin, Berlin
Import activity
65
Industries
Automotive
Electric Vehicles
Medical
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
65
Named foreign suppliers
7
Top origins
Spain · Italy · Belgium

Shared foreign counterparties do not establish that these companies buy from Medios.
What this tells a buyer
Medios receives shipments from suppliers across Spain, Italy, and Belgium, with over 1,700 recorded inbound shipments from sources including Sefar and Saati.
The company offers compounding of custom medications, cytostatic drug manufacturing, specialized antibody therapies, and wholesale distribution of high-priced specialty drugs, supported by Medios Digital software solutions for operational efficiency.
Medios set an ambition in 2026 to reach €3.1 billion in revenue and double adjusted EBITDA by 2031, reflecting expansion in its specialty pharma operations.
Source: US customs bill-of-lading records and public filings · Last verified Nov 13, 2026
STABILITY SIGNALS
Operating
11 years in operation (founded 2015).
65 US import shipments on record.
Overview
Medios is a Berlin-based specialty pharmaceutical provider established in 2015, operating across Germany, the Netherlands, Belgium, and Spain with 500-1,000 employees and estimated revenue of €1.8 billion as of 2023. The company composes patient-specific medications, manufactures cytostatic drugs, and distributes high-priced specialty pharmaceuticals for oncology and neurology therapies. Medios acquired a 74% stake in Caelo in 2026 to strengthen its position in active pharmaceutical ingredients and excipients across Europe.
At a glance
Attribute | Detail |
|---|---|
Founded | 2015 |
Headquarters | Berlin, Berlin |
Employees | 500-1,000 |
Revenue | $1-5B (estimated) |
Primary capability | Electronics & Software |
What Medios makes
The company offers compounding of custom medications, cytostatic drug manufacturing, specialized antibody therapies, and wholesale distribution of high-priced specialty drugs, supported by Medios Digital software solutions for operational efficiency.
Trade and customs footprint
Medios receives shipments from suppliers across Spain, Italy, and Belgium, with over 1,700 recorded inbound shipments from sources including Sefar and Saati. US customs bill-of-lading records list 65 inbound shipments across 7 foreign suppliers, with top origins including Spain · Italy · Belgium.
Latest developments
2026-11-10 — Medios Achieves Solid Revenue Growth in a Challenging Market Environment and Confirms Full-Year Forecast | Corporate - EQS News (eqs-news.com)
2026-09-29 — Medios sets out Ambition 2031: €3.1 billion revenue and a doubling of EBITDA adjusted | Corporate - EQS News (eqs-news.com)
2026-08-12 — Medios continues growth path in the first half of 2026 and focuses on profitability and cash conversion | Corporate - EQS News (eqs-news.com)
2026-08-11 — Medios Acquires a 74% Majority Stake in Caelo and Strengthens Its German and European Business in Active Pharmaceutical Ingredients and Excipients | Corporate - EQS News (eqs-news.com)
2026-01-19 — Medios wordt exclusieve distributeur van Bedrocan (bedrocan.com)
2026-01-19 — Medios AG | (finanzwire.com)
Company details
Medios set an ambition in 2026 to reach €3.1 billion in revenue and double adjusted EBITDA by 2031, reflecting expansion in its specialty pharma operations. Medios was founded in 2015, has an estimated 500-1,000 employees, and is headquartered in Berlin, Berlin. On the LightSource stability read it is rated "Operating": 11 years in operation (founded 2015). 65 US import shipments on record.
Frequently asked questions
What does Medios make?
Medios is a Berlin-based specialty pharmaceutical provider established in 2015, operating across Germany, the Netherlands, Belgium, and Spain with 500-1,000 employees and estimated revenue of €1.8 billion as of 2023. The company composes patient-specific medications, manufactures cytostatic drugs, and distributes high-priced specialty pharmaceuticals for oncology and neurology therapies. Medios acquired a 74% stake in Caelo in 2026 to strengthen its position in active pharmaceutical ingredients and excipients across Europe.
Where is Medios headquartered?
Medios is headquartered in Berlin, Berlin.
When was Medios founded?
Medios was founded in 2015.
How big is Medios?
Medios has an estimated 500-1,000 employees, with revenue in the $1-5B range (estimated).
Does Medios import from overseas suppliers?
US customs bill-of-lading records show 65 inbound shipments for Medios, with top origins including Spain · Italy · Belgium.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
